Exercise during curative chemotherapy for breast cancer has proven benefits. It helps reduce fatigue, preserve muscle strength, improve fitness, and enhance overall quality of life. Staying physically active…
With a wave of FDA approvals and promising clinical trials, treatment options for metastatic breast cancer are expanding fast. Amy Tiersten, MD, highlights the power of immunotherapies—especially checkpoint…
A treatment is undergoing development in hopes to receive FDA clearance to be the first drug targeted at the third- and fourth-line space in patients with refractory renal cell carcinoma…
Can targeted therapies offer safer and more efficient means to treat patients with acute myeloid leukemia (AML)? Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park…
Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center, describes acute myeloid leukemia (AML) and details how emerging targeted treatments are transforming the…
In this interview, Omid Hamid, MD, discusses the current landscape of targeted therapies in melanoma. He shares his thoughts about immune response, triplet therapy, and soon-to-be-released data that…
Mark M. Awad, MD, PhD, assistant professor of Medicine at Harvard Medical School and clinical director of the Thoracic Oncology Treatment Center at Dana-Farber Cancer Institute, shares insights…
In this “Practice Pearls” roundtable organized by Pharmacy Times, expert panelists discuss acute myeloid leukemia (AML) diagnosis and the various factors affecting decision-making for specialists treating patients with…
Paula J. Bates, PhD, professor of medicine at the University of Louisville School of Medicine, and colleagues John O. Trent, PhD, and Donald M. Miller, MD, PhD, have…
A study published in Clinical Cancer Research, authored by James Brugarolas, MD, PhD, professor of internal medicine (hematology/oncology) and director of the Kidney Cancer Program at UT Southwestern, demonstrated…
Jason J. Luke, MD, FACP, an associate professor of medicine in the Division of Hematology/Oncology and director of the Cancer Immunotherapeutics Center within the Immunology and Immunotherapy Program at…
A study composed of patients from across the USA and Europe observed improved outcomes in those treated with both ilixadencel and sunitinib compared with sunitinib alone. here.